Entera Bio (NASDAQ:ENTX - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright's price objective points to a potential upside of 468.18% from the company's previous close.
Entera Bio Stock Performance
Shares of Entera Bio stock traded up $0.04 on Monday, reaching $1.76. The company had a trading volume of 82,907 shares, compared to its average volume of 116,981. The firm's 50 day moving average price is $1.87 and its two-hundred day moving average price is $1.92. Entera Bio has a 52-week low of $0.52 and a 52-week high of $3.35. The firm has a market cap of $62.97 million, a PE ratio of -6.62 and a beta of 1.58.
Entera Bio (NASDAQ:ENTX - Get Free Report) last posted its earnings results on Friday, November 8th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. As a group, sell-side analysts predict that Entera Bio will post -0.23 EPS for the current year.
Hedge Funds Weigh In On Entera Bio
A hedge fund recently bought a new stake in Entera Bio stock. Signature Estate & Investment Advisors LLC bought a new stake in Entera Bio Ltd. (NASDAQ:ENTX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 47,328 shares of the company's stock, valued at approximately $90,000. Signature Estate & Investment Advisors LLC owned about 0.13% of Entera Bio at the end of the most recent quarter. 14.11% of the stock is currently owned by institutional investors and hedge funds.
Entera Bio Company Profile
(
Get Free Report)
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Further Reading
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
